Back to Insights

Ori Biotech featured on the Life Sciences Knowledge Hub with David McLelland.

Jason C. Foster discusses the importance of the work Ori is doing to address barriers to access for cell and gene therapies, highlighting the urgent need for innovation in the CGT manufacturing technology space.

Ori has developed a proprietary, flexible manufacturing platform that closes, automates, and standardizes CGT manufacturing allowing therapeutics developers to bring products to market at commercial scale. The promise of the full stack Ori platform is to fully automate CGT manufacturing to increase throughput, improve quality, and decrease costs by combining hardware, software, and data services, enabling broader access to these lifesaving treatments.

More on:

Watch full interview:

Share this page